Novo Nordisk - Database of Clinical Trials by Pharmaceutical Companies

All Categories Pharma Companies » Novo Nordisk

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Conditions: Haemostasis; Trauma
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Conditions: Haemostasis; Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NNC 0148-0000-0362; Drug: insulin glargine; Drug: placebo; Drug: NNC 0148-0000-0362; Drug: NNC 0148-0000-0362; Drug: NNC 0148-0000-0362
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women

Conditions: Menopause; Healthy
Intervention: Drug: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin degludec/insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

Condition: Adult Growth Hormone Deficiency
Intervention: Drug: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified April 2012
French National Registry of Children Born Small for Gestational Age Treated With Somatropin

Condition: Small for Gestational Age
Interventions: Drug: No treatment given; Drug: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified April 2012
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Conditions: Haemophilia; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Conditions: Haemophilia; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Conditions: Haemophilia; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: insulin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
Investigation of Optimal Dosing Conditions for NN9924 in Healthy Male Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Conditions: Acquired Bleeding Disorder; Intracerebral Haemorrhage
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Conditions: Acquired Bleeding Disorder; Bleeding Following Stem Cell Transplantation
Interventions: Drug: standard therapy; Drug: placebo; Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Terminated - verified March 2012
Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Other: No treatment given; Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Conditions: Acquired Bleeding Disorder; Intracerebral Haemorrhage
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Conditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Other: factor IX; Drug: factor VIII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Conditions: Haemostasis; Bone Marrow Transplantation
Intervention: Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Conditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Conditions: Haemostasis; Healthy
Interventions: Drug: warfarin; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Conditions: Haemostasis; Healthy
Interventions: Drug: activated recombinant human factor VII; Drug: clopidogrel; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Terminated - verified March 2012
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0114-0006; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified March 2012
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Conditions: Acquired Bleeding Disorder; Trauma
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Conditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors; Healthy
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Conditions: Growth Hormone Deficiency in Children; Turner Syndrome
Intervention: Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Conditions: Acquired Bleeding Disorder; Bleeding Following Stem Cell Transplantation
Interventions: Procedure: standard therapy; Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Conditions: Haemophilia A; Haemophilia B
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Conditions: Haemostasis; Chronic Liver Disease
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Conditions: Acquired Bleeding Disorder; Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: repaglinide; Drug: insulin NPH
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Conditions: Haemostasis; Chronic Liver Disease
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

Condition: Adult Growth Hormone Deficiency
Interventions: Drug: somatropin; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Conditions: Haemophilia A; Haemophilia B
Intervention: Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Conditions: Acquired Haemophilia; Congenital FVII Deficiency; Glanzmann's Disease; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors; Healthy
Interventions: Drug: activated recombinant human factor VII; Drug: activated recombinant human factor VII
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Conditions: Obesity; Obstructive Sleep Apnoea
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012
Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Conditions: Haemophilia; Haemophilia A; Haemophilia B; Healthy
Interventions: Drug: NNC172-2021; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study

Condition: Acute Leukemia
Intervention: Behavioral: Health counseling and exercise
Sponsors: Universitetshospitalernes Center for Sygepleje; Universitetshospitalernes Center for Sygepleje; Novo Nordisk; Lundbeck Foundation
Completed - verified March 2012
Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Levemir® Used as Basal Insulin

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Safety and Efficacy of Long-term Somatropin Treatment in Adults

Condition: Adult Growth Hormone Deficiency
Intervention: Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified February 2012
Safety and Efficacy of Long-term Somatropin Treatment in Children

Conditions: Growth Hormone Deficiency in Children; Small for Gestational Age; Turner Syndrome; Idiopathic Short Stature
Intervention: Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012
Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients

Conditions: Perioperative and Postoperative Hyperglycemia; Tight Glycemia Control
Intervention: Procedure: Intensive glycemia control
Sponsors: Charles University, Czech Republic; Charles University, Czech Republic
Active, not recruiting - verified March 2012
The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism

Conditions: Type 2 Diabetes; Dyslipidemia
Interventions: Drug: Insulin; Drug: insulin; Other: diet; Other: no diet
Sponsors: University of Aarhus; University of Aarhus
Not yet recruiting - verified March 2012
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin detemir; Drug: insulin NPH
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin aspart; Drug: human soluble insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Liraglutide Effects on Memory in Healthy Subjects

Condition: Healthy
Interventions: Drug: liraglutide; Drug: Placebo
Sponsors: University of Luebeck; University of Luebeck; Novo Nordisk
Not yet recruiting - verified March 2012
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 30; Drug: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Effect of Personal Versus Video Instruction in Elastic Resistance Exercise on Technical Execution (IRMA05)

Condition: Musculoskeletal Disorders
Interventions: Behavioral: Video instruction; Behavioral: Personal instruction
Sponsors: National Research Centre for the Working Environment, Denmark; National Research Centre for the Working Environment, Denmark; Novo Nordisk
Not yet recruiting - verified February 2012
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified May 2012
Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 50; Drug: biphasic insulin aspart 70; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Paediatric Subjects - Special Survey

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Special Survey for Patients With Type 1 or Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Liraglutide Use in Prader-Willi Syndrome

Conditions: Diabetes Mellitus Type 2; Prader Willi Syndrome
Intervention: Drug: Liraglutide
Sponsors: Vancouver General Hospital; Vancouver General Hospital; Novo Nordisk
Active, not recruiting - verified February 2012
Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)

Conditions: Diabetes; Healthy
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic insulin aspart 70
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic insulin aspart 70
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 70; Drug: biphasic human insulin 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 70
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 70
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 30; Drug: sitagliptin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2012
Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Conditions: Diabetes; Healthy
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 50; Drug: biphasic insulin aspart 70; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 50; Drug: biphasic insulin aspart 70; Drug: biphasic human insulin 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Two Formulations of Biphasic Insulin Aspart 70

Conditions: Diabetes; Healthy
Interventions: Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: moxifloxacin; Drug: placebo; Procedure: electrocardiogram (ECG); Procedure: electrocardiogram (ECG)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: [3H]-liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: paracetamol
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Use of Somatropin in Turner Syndrome

Condition: Turner Syndrome
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Condition: Turner Syndrome
Interventions: Drug: somatropin; Drug: somatropin; Drug: somatropin; Drug: oestrogen
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Special Survey for Long Term Application

Condition: Achondroplasia
Intervention: Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Evaluation of Safety and Parameters of Application Technique

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Two Liraglutide Formulations in Healthy Subjects

Conditions: Diabetes; Healthy
Interventions: Drug: liraglutide; Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: liraglutide; Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Conditions: Diabetes; Healthy
Interventions: Drug: liraglutide; Drug: placebo; Drug: atorvastatin; Drug: lisinopril; Drug: liraglutide; Drug: placebo; Drug: griseofulvin; Drug: digoxin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Three Liraglutide Formulations in Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/insulin aspart; Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified May 2012
Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
First Human Dose Trial of NNC0195-0092 in Healthy Subjects

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Deficiency in Children; Healthy
Interventions: Drug: NNC0195-0092; Drug: placebo; Drug: NNC0195-0092; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: placebo; Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Conditions: Growth Hormone Deficiency; Healthy
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified March 2012
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

Conditions: Diabetes; Healthy
Interventions: Drug: NNC 90-1170; Drug: placebo; Drug: NNC 90-1170; Drug: NNC 90-1170; Drug: insulin human; Drug: insulin human; Drug: NNC 90-1170
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU Agent in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: metformin; Drug: placebo; Drug: placebo; Drug: glimepiride
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: placebo; Drug: glimepiride
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified May 2012
Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: levonorgestrel / ethinylestradiol
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Two Liraglutide Formulations in Healthy Volunteers

Conditions: Diabetes; Healthy
Interventions: Drug: liraglutide; Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Diabetes Attitudes Wishes and Needs

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Relatives to/Carers of Patients; Healthcare Professionals
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified March 2012
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: placebo; Drug: NNC 90-1170; Drug: glimepiride
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Conditions: Diabetes; Healthy
Interventions: Drug: NNC 90-1170; Drug: NNC 90-1170; Drug: placebo; Drug: NNC 90-1170
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Conditions: Menopause; Postmenopausal Vaginal Atrophy
Intervention: Drug: estradiol, 25 mcg
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Condition: Noonan Syndrome
Interventions: Other: No treatment given; Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Condition: Noonan Syndrome
Interventions: Other: No treatment given; Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified February 2012
Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries

Conditions: Haemophilia A; Haemophilia A With Inhibitors; Haemophilia B; Haemophilia B With Inhibitors
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified April 2012
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

Condition: Growth Hormone Deficiency in Children
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
The Luteal Phase After GnRHa Trigger - a Proof of Concept Study

Condition: Hormone Levels (Progesterone)
Interventions: Drug: hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase; Drug: hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase; Drug: LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase; Drug: vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase
Sponsors: Regionshospitalet Viborg, Skive; Regionshospitalet Viborg, Skive
Not yet recruiting - verified January 2012
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis

Conditions: Growth Hormone Deficiency; Chronic Renal Insufficiency
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Conditions: Type 2 Diabetes Mellitus; Obesity
Interventions: Drug: Liraglutide; Drug: Saline
Sponsors: University of Texas Southwestern Medical Center; Ildiko Lingvay; Novo Nordisk
Recruiting - verified January 2012
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin NPH
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™

Conditions: Growth Hormone Deficiency in Children; Delivery Systems
Intervention: Device: NordiFlex PenMate™
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Comparison of Two Insulin Detemir Formulations in Healthy Volunteers

Conditions: Diabetes; Healthy
Interventions: Drug: insulin detemir; Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Observational Study of NovoNorm® in Subjects With Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: repaglinide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: repaglinide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Within-subject Variability of Insulin Detemir in Healthy Volunteers

Conditions: Diabetes; Healthy
Interventions: Drug: insulin detemir; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin detemir; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin NPH
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan

Conditions: Diabetes; Healthy
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Conditions: Haemophilia; Haemophilia A
Intervention: Drug: NNC 0155-0000-0004
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1

Conditions: Diabetes; Diabetes Mellitus, Type 1
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified March 2012
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic human insulin 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic human insulin 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic human insulin; Drug: isophane human insulin; Drug: human soluble insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin human
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: repaglinide; Drug: metformin; Drug: repaglinide and metformin combination tablet
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: repaglinide; Drug: metformin; Drug: repaglinide and metformin combination tablet
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Observational Study With InnoLet® in Daily Clinical Practice

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin human
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin detemir; Drug: insulin aspart; Drug: insulin NPH; Drug: human soluble insulin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Surveillance Study of NovoRapid® for New Drug Re-examination

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Bioequivalence of Two Insulatard® Formulations in Healthy Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: isophane human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin detemir; Drug: insulin aspart; Drug: insulin NPH; Drug: human soluble insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Conditions: Diabetes; Healthy
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: biphasic human insulin 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis

Conditions: Menopause; Postmenopausal Vaginal Atrophy
Interventions: Drug: estradiol, 10 mcg; Drug: estradiol, 25 mcg
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic human insulin 30; Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy

Condition: Menopause
Intervention: Drug: Marketed low dose hormone replacement therapy
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology

Conditions: Hemorrhage; Bleeding
Intervention: Other: observational study
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble; Novo Nordisk; Société Française d'Anesthésie et de Réanimation (SFAR)
Recruiting - verified February 2012
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes

Condition: Type 2 Diabetes
Intervention: Drug: liraglutide
Sponsors: Steno Diabetes Center; Peter Rossing; Novo Nordisk
Not yet recruiting - verified December 2011
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Conditions: Diabetes; Diabetes Mellitus, Type 2; Medullary Thyroid Carcinoma
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified January 2012
Special Survey for Paediatric Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Special Survey of Production of Insulin Aspart Specific Antibody

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Special Survey for Type 1 or Type 2 Diabetic Patients

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A

Condition: Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2012
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Condition: Haemophilia A
Interventions: Drug: NNC 0129-0000-1003; Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin aspart; Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Fat and Transcapillary Insulin Transport

Condition: Lipid-induced Insulin Resistance
Interventions: Other: Elevation of FFA during OGTT; Other: Elevation of FFA during Clamp
Sponsors: German Diabetes Center; German Diabetes Center; Medical University of Vienna
Not yet recruiting - verified November 2011
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: insulin
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified December 2011
Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women

Conditions: Menopause; Healthy
Interventions: Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA); Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA); Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: NN1218; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: liraglutide-depot; Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified April 2012
Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin aspart; Drug: human insulin; Drug: isophane human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart; Drug: biphasic human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart; Drug: biphasic human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Conditions: Hyperglycemia; Chronic Heart Failure
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Flyvbjerg, Allan, DMSc; Flyvbjerg, Allan, DMSc; Novo Nordisk
Not yet recruiting - verified November 2011
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin aspart; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B

Conditions: Congenital Bleeding Disorder; Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified February 2012
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: NN1250
Sponsors: Novo Nordisk; Novo Nordisk
Terminated - verified January 2012
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: repaglinide
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"

Conditions: Obesity; Insulin Resistance; Type 2-diabetes; Inflammation
Intervention: Procedure: gastric bypass
Sponsors: University of Aarhus; University of Aarhus; Novo Nordisk; The Danish Medical Research Council
Recruiting - verified November 2011
A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: IDegAsp
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems
Interventions: Device: FlexPen®; Device: NovoPen® 3
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified April 2012
Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Conditions: Congenital Bleeding Disorder; Glanzmann's Disease
Intervention: Drug: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified March 2012
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers

Conditions: Diabetes; Healthy
Intervention: Drug: human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified October 2011
DiaCon Overnight Closed-Loop Glucose Control Study

Condition: Type 1 Diabetes
Interventions: Device: Closed-loop control; Other: Open-loop control
Sponsors: Hvidovre University Hospital; Hvidovre University Hospital; Technical University of Denmark; Novo Nordisk
Not yet recruiting - verified September 2011
Pharmacology of Insulin Injected With Jet-injection in Diabetes

Condition: Diabetes Mellitus
Intervention: Device: jet injection device
Sponsors: Radboud University; Radboud University; European Pharma Group (EPG)
Recruiting - verified August 2011
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Condition: Achondroplasia
Intervention: Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified January 2012
Comparing Long-acting Insulins During Exercise in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glargine; Drug: Insulin detemir
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Novo Nordisk
Recruiting - verified November 2011
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

Conditions: Diabetes; Healthy
Intervention: Drug: NN1250
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified November 2011
Changing Diabetes® World Tour

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1
Intervention: Other: No treatment given
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Respectively, Both Combined With Metformin in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Intervention: Drug: biphasic insulin aspart 30
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified February 2012
Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects

Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: oral NNC 0113-0987; Drug: oral NNC 0113-0987; Drug: I.v. NNC 0113-0987; Drug: oral placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

Condition: Healthy
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified October 2011
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2
Intervention: Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Enrolling by invitation - verified December 2011
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Intervention: Drug: Liraglutide-metformin vs insulin-metformin
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Diabete Quebec; Radiological Society of North America Research and Education Foundation; Canadian Heads of Academic Radiology-GE Healthcare Development Award
Recruiting - verified July 2011
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

Conditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Interventions: Drug: NNC 0078-0000-0007; Drug: eptacog alfa (activated)
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Pharmacodynamics of CNP During Growth Hormone Treatment

Conditions: Pituitary Dwarfism; Idiopathic Short Stature
Intervention:
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Children's Hospital Los Angeles; Novo Nordisk
Enrolling by invitation - verified February 2012
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: insulin degludec
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified March 2012
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin aspart; Drug: liraglutide
Sponsors: Novo Nordisk; Novo Nordisk
Active, not recruiting - verified January 2012
Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function

Conditions: Kidney Transplantation; Delayed Graft Function; Acute Kidney Injury; Glomerular Filtration Rate
Intervention: Other: Remote ischemic conditioning
Sponsors: University of Aarhus; University of Aarhus; Sahlgrenska University Hospital, Sweden; Lundbeck Foundation; Novo Nordisk
Recruiting - verified March 2012
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Condition: Haemophilia B
Interventions: Drug: NNC-0156-0000-0009; Drug: NNC-0156-0000-0009; Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

Condition: Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012
Liraglutide Treatment to Patients With Severe Renal Insufficiency

Conditions: Type 2 Diabetes Mellitus; End-stage Renal Disease
Intervention: Drug: Liraglutide
Sponsors: Rigshospitalet, Denmark; Bo Feldt-Rasmussen; Novo Nordisk; The GCP unit at Copenhagen University Hospital
Recruiting - verified September 2011
Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle

Condition: Infertility
Interventions: Drug: estradiol tablet; Drug: estradiol tablet
Sponsors: Zekai Tahir Burak Maternity and Teaching Hospital; Zekai Tahir Burak Maternity and Teaching Hospital
Completed - verified November 2008
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: IDegAsp; Drug: IDegAsp
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin degludec
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012
Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Conditions: Rheumatoid Arthritis; Inflammation
Interventions: Drug: NNC 0141-0000-0100; Drug: placebo; Drug: NNC 0141-0000-0100; Drug: placebo; Drug: NNC 0141-0000-0100; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified January 2012
A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Condition: Haemophilia A
Intervention: Drug: NNC 0155-0000-0004
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified September 2011